title,time_published,url,ticker,relevance_score,ticker_sentiment_label,ticker_sentiment_score
Stocks That Hit 52-Week Lows On Thursday,20220428T193101,https://www.benzinga.com/markets/options/22/04/26872967/52-weeks-high-and-low-article,ABUS,0.00644,Neutral,0.034847
Is Arbutus Biopharma  ( ABUS )  Outperforming Other Medical Stocks This Year?,20240806T134012,https://www.zacks.com/stock/news/2316975/is-arbutus-biopharma-abus-outperforming-other-medical-stocks-this-year,ABUS,0.800175,Bullish,0.443113
Bispecific Antibody Clinical Trial Pipeline Appears Robust With 250+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight,20230703T210100,https://www.prnewswire.com/news-releases/bispecific-antibody-clinical-trial-pipeline-appears-robust-with-250-key-pharma-companies-actively-working-in-the-therapeutics-segment--delveinsight-301868673.html,ABUS,0.020404,Neutral,-0.004464
"Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate",20220804T130628,https://www.benzinga.com/general/biotech/22/08/28353376/biotech-daily-amgen-gilead-go-shopping-nod-for-astrazenecas-lynparza-in-early-stage-breast-cancer,ABUS,0.09989,Neutral,0.0
RNAi Therapeutics Global Market to 2027: Rising Utilization in Oncology Pharmaceuticals and Accelerating Growth Rates of Infectious Diseases Drives Growth,20230316T184500,https://www.prnewswire.com/news-releases/rnai-therapeutics-global-market-to-2027-rising-utilization-in-oncology-pharmaceuticals-and-accelerating-growth-rates-of-infectious-diseases-drives-growth-301774181.html,ABUS,0.044801,Neutral,0.145391
Longtime Gilead Commercial Executive Joins IntegriChain as Chairman of the Board,20240228T150000,https://www.prnewswire.com/news-releases/longtime-gilead-commercial-executive-joins-integrichain-as-chairman-of-the-board-302073845.html,ABUS,0.05749,Neutral,0.04899
"Earnings Scheduled For May 5, 2022",20220505T084322,https://www.benzinga.com/news/earnings/22/05/27012606/earnings-scheduled-for-may-5-2022,ABUS,0.009774,Neutral,-0.063514
